A Phase 1a, Repeat-Dose Escalation Study to Investigate the Safety and Tolerability of a 7-Day Repeated Dose of Retinoid QLT091001 in Healthy Volunteers
Latest Information Update: 04 Dec 2013
Price :
$35 *
At a glance
- Drugs Zuretinol acetate (Primary)
- Indications Age-related macular degeneration; Leber congenital amaurosis; Retinitis pigmentosa
- Focus Adverse reactions
- Sponsors QLT
- 04 Dec 2013 New trial record
- 28 Mar 2009 Status changed from recruiting to completed.